Artelo Biosciences, Inc.
ARTL· Nasdaq
ARTLArtelo Biosciences, Inc.
Filed Aug 13, 2024 · 10-Q · 44 days after period end · 0001640334-24-001221
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$2.43M | -$1.60M | -$2.45M | -$2.25M |
| EPS Diluted | -$4.52 | — | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Artelo Biosciences, Inc. · CIK 1621221 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end
